VRTX Clinical trials

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Published August 04, 2025 at 08:01 PM

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of t

Related Questions

What will be the immediate impact of the Phase 2 results on VRTX's stock price? Could the results lead to a strategic partnership, licensing deal, or asset divestiture for Vertex? What are the implications for Vertex's overall pipeline valuation given this setback? What are the potential financial implications of extending or redesigning the VX-993 program? How does VX-993's performance stack up against competitors' NaV1.8 inhibitors or other acute pain modalities? What is the expected cost and cash burn associated with further development of VX-993? Will Vertex pursue a Phase 3 trial despite the lack of statistically significant efficacy in this study? How do the safety and tolerability data from this trial compare to existing acute pain treatments? How might the market’s perception of Vertex’s R&D capabilities change after this disclosure? How does the failure to meet the primary endpoint affect the timeline for VX-993's regulatory approval?